KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Consolidated Net Income (2016 - 2025)

NovoCure (NVCR) has disclosed Consolidated Net Income for 12 consecutive years, with -$24.5 million as the latest value for Q4 2025.

  • Quarterly Consolidated Net Income rose 62.84% to -$24.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$136.2 million through Dec 2025, up 19.21% year-over-year, with the annual reading at -$136.2 million for FY2025, 19.21% up from the prior year.
  • Consolidated Net Income hit -$24.5 million in Q4 2025 for NovoCure, up from -$37.3 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of -$4.1 million in Q1 2021 to a low of -$65.9 million in Q4 2024.
  • Historically, Consolidated Net Income has averaged -$33.1 million across 5 years, with a median of -$33.8 million in 2024.
  • Biggest five-year swings in Consolidated Net Income: plummeted 1041.83% in 2023 and later surged 62.84% in 2025.
  • Year by year, Consolidated Net Income stood at -$26.5 million in 2021, then crashed by 40.99% to -$37.3 million in 2022, then fell by 26.21% to -$47.1 million in 2023, then tumbled by 40.02% to -$65.9 million in 2024, then soared by 62.84% to -$24.5 million in 2025.
  • Business Quant data shows Consolidated Net Income for NVCR at -$24.5 million in Q4 2025, -$37.3 million in Q3 2025, and -$40.1 million in Q2 2025.